Calcium or Magnesium Chloride Composition for Rapid PTP Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for hydrating the larynx and trachea are inefficient in reducing phonation threshold pressure (PTP) and addressing cough incidence, voice quality issues, and respiratory disorders such as asthma, particularly in dehydrated conditions.
Innovation Solution
Delivering isotonic or hypertonic salt-based formulations, such as calcium or magnesium chloride, through nasal or oral inhalation as aerosols or sprays with targeted droplet sizes (8-15 microns) to deposit at least 0.1 mg of salt in the larynx and trachea, maintaining a pH of 7.0 to 10.0, preferably 8.0 to 9.5, to lower PTP and improve hydration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If traditional hydration methods (drinking water) are used, then hydration is achieved, but the effect is slow and insufficient for rapid PTP reduction
Solution Approach 1:
The patent uses aerosol delivery systems (nebulizers, ultrasonic sprays) to transport salt-based formulations through the respiratory tract directly to the larynx and trachea. This pneumatic/hydraulic delivery mechanism enables rapid deposition of salt (at least 0.1 mg) in the target area, achieving PTP reduction within 15 minutes, whereas oral hydration methods are significantly slower.
Solution Approach 2:
The patent targets specific locations (larynx and trachea) with salt-based formulations delivered via inhalation, concentrating the hydrating effect locally rather than relying on systemic hydration through drinking. This localized delivery ensures sufficient salt concentration (at least 0.1 mg) is achieved rapidly in the specific area needing hydration.
2Manufacturing precision
If salt-based formulations are delivered via inhalation, then rapid hydration and PTP reduction are achieved, but delivery precision and deposition control become critical
Solution Approach 1:
The patent optimizes aerosol parameters including droplet size (8-15 microns for nasal delivery, smaller for oral delivery), salt concentration (isotonic to hypertonic formulations), and delivery timing to ensure precise deposition of at least 0.1 mg of salt in the larynx and trachea. These parameter adjustments enable controlled delivery without requiring overly complex device architecture.
3Reliability
If hypertonic salt solutions are used, then hydration effect is enhanced, but pH control becomes critical to avoid tissue irritation
Solution Approach 1:
The patent formulates salt-based compositions with controlled pH levels (7.0 to 10.0, preferably 8.0 to 9.5) to balance hydration effectiveness with tissue compatibility. This parameter control ensures the hypertonic salt solution provides sufficient osmotic drive for water movement while minimizing irritation to the laryngeal and tracheal tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces PTP by 5-30% within 15 minutes, lasting up to 120 minutes, improving voice quality, reducing cough incidence, and treating disorders like asthma by enhancing air flow and oxygen saturation.
Implementation Method 1
Delivering isotonic or hypertonic salt-based formulations or compositions breathed through the nose or mouth and that deliver into the nose or mouth at least approximately 0.3 mg of total salt... and treatment protocols, devices, and articles suitable for the depositing at least approximately 0.1 mg of salt-based compositions to the larynx and other tissue surrounding or in the vicinity of the larynx in a respiratory tract of the subject
Implementation Method 2
hydration treatments of a relatively non-hydrated larynx and trachea... to reduce phonation threshold pressure... improving voice quality... reducing cough incidence
Data Source
AI summary
Hydration of a larynx and/or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and/or NaCl) can achieve prophylactic and/or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and/or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.